JP5909447B2 - ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー - Google Patents

ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー Download PDF

Info

Publication number
JP5909447B2
JP5909447B2 JP2012528991A JP2012528991A JP5909447B2 JP 5909447 B2 JP5909447 B2 JP 5909447B2 JP 2012528991 A JP2012528991 A JP 2012528991A JP 2012528991 A JP2012528991 A JP 2012528991A JP 5909447 B2 JP5909447 B2 JP 5909447B2
Authority
JP
Japan
Prior art keywords
biomarker
tau
gfap
injury
calpain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012528991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504331A (ja
JP2013504331A5 (enExample
Inventor
ワン，ケヴィン，カ−ワン
ツァン，ツィクン
リウ，ミン，チェン
ヘイズ，ロナルド，エル．
Original Assignee
バンヤン・バイオマーカーズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43733138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5909447(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by バンヤン・バイオマーカーズ・インコーポレーテッド filed Critical バンヤン・バイオマーカーズ・インコーポレーテッド
Publication of JP2013504331A publication Critical patent/JP2013504331A/ja
Publication of JP2013504331A5 publication Critical patent/JP2013504331A5/ja
Application granted granted Critical
Publication of JP5909447B2 publication Critical patent/JP5909447B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2012528991A 2009-09-14 2010-09-14 ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー Active JP5909447B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24212309P 2009-09-14 2009-09-14
US61/242,123 2009-09-14
US35450410P 2010-06-14 2010-06-14
US61/354,504 2010-06-14
US35577910P 2010-06-17 2010-06-17
US61/355,779 2010-06-17
US38015810P 2010-09-03 2010-09-03
US61/380,158 2010-09-03
PCT/US2010/048789 WO2011032155A2 (en) 2009-09-14 2010-09-14 Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015253708A Division JP2016105097A (ja) 2009-09-14 2015-12-25 ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー

Publications (3)

Publication Number Publication Date
JP2013504331A JP2013504331A (ja) 2013-02-07
JP2013504331A5 JP2013504331A5 (enExample) 2013-12-19
JP5909447B2 true JP5909447B2 (ja) 2016-04-26

Family

ID=43733138

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012528991A Active JP5909447B2 (ja) 2009-09-14 2010-09-14 ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
JP2015253708A Pending JP2016105097A (ja) 2009-09-14 2015-12-25 ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
JP2017111070A Active JP6469760B2 (ja) 2009-09-14 2017-06-05 ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015253708A Pending JP2016105097A (ja) 2009-09-14 2015-12-25 ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
JP2017111070A Active JP6469760B2 (ja) 2009-09-14 2017-06-05 ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー

Country Status (8)

Country Link
US (3) US20130022982A1 (enExample)
EP (1) EP2478360B1 (enExample)
JP (3) JP5909447B2 (enExample)
AU (2) AU2010291933B2 (enExample)
CA (1) CA2774173A1 (enExample)
ES (1) ES2687469T3 (enExample)
HU (1) HUE040281T2 (enExample)
WO (1) WO2011032155A2 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
WO2010019553A2 (en) 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
CA2766057A1 (en) * 2009-06-19 2010-12-23 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20170315136A9 (en) * 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
WO2012045324A1 (en) * 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
WO2012051519A2 (en) 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
DE102011011280A1 (de) * 2011-02-15 2012-08-16 Euroimmun Medizinische Labordiagnostika Ag Diagnosekit sowie ein Verfahren zur Untersuchung einer menschlichen Patientenprobe auf das Vorhandensein von Neuromyelitis-optica-spezifischen Antikörpern
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
US20140206777A1 (en) * 2011-08-16 2014-07-24 Rosetta Genomics Ltd. Methods and compositions for diagnosis of alzheimer's disease
US9709573B2 (en) 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
WO2013173596A1 (en) * 2012-05-16 2013-11-21 Trustees Of Boston University Chronic traumatic encephalopathy in blast-exposed individuals
NZ703423A (en) * 2012-07-03 2018-02-23 Univ Washington Antibodies to tau
US20140073524A1 (en) * 2012-09-07 2014-03-13 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (ptsd)
US9856532B2 (en) * 2012-09-07 2018-01-02 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (PTSD)
EP3022322A4 (en) 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
GB201319761D0 (en) * 2013-11-08 2013-12-25 Nordic Bioscience As Biomarkers of disease progression
CN103656685B (zh) * 2014-01-10 2016-01-13 厦门大学 microRNA-219在制备抗癫痫药物中的应用
WO2015134551A1 (en) * 2014-03-03 2015-09-11 Banyan Biomarkers, Inc. Micro rna markers for diagnosis of a neurological condition
US9605315B2 (en) 2014-03-26 2017-03-28 The University Of Montana Detection of traumatic brain injury
CN106461645A (zh) * 2014-04-07 2017-02-22 铁马诊断公司 外伤性脑损伤和神经退行性生物标记物、方法和系统
EP3129788A4 (en) * 2014-04-08 2018-04-04 University of Florida Research Foundation, Incorporated Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
WO2015160391A1 (en) * 2014-04-15 2015-10-22 The Government Of The United States, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research Diagnosis and treatment of tauopathy and chronic traumatic encephalopathy
WO2015196191A1 (en) * 2014-06-20 2015-12-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Microrna biomarkers for traumatic brain injury and methods of use thereof
US10358679B2 (en) * 2014-09-26 2019-07-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. MicroRNA biomarkers for posttraumatic stress disorder and methods of use thereof
US20180238907A1 (en) * 2014-10-06 2018-08-23 Université de Genéve Markers and their use in brain injury
EP3254106A4 (en) * 2015-02-05 2018-10-03 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
WO2016205730A1 (en) * 2015-06-18 2016-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Citrullinated proteins and their breakdown products as tbi biomarkers
WO2017019976A2 (en) * 2015-07-29 2017-02-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Microrna biomarkers for traumatic brain injury and methods of use thereof
WO2017044650A1 (en) * 2015-09-08 2017-03-16 The Translational Genomics Research Institute Biomarkers and methods of diagnosing and prognosing mild traumatic brain injuries
EP3377074B1 (en) * 2015-11-18 2024-01-03 Dignity Health Methods of diagnosing post traumatic epilepsy
GB201603967D0 (en) 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
CN109219655A (zh) * 2016-04-28 2019-01-15 般财团法人生产技术研究奖励会 用于培养神经细胞的装置、用于培养神经细胞的方法、培养的神经细胞、用于分析和鉴定轴突束中蛋白质的方法、以及用于使用神经细胞的方法
JP2019521319A (ja) * 2016-05-06 2019-07-25 デューク ユニバーシティ 神経系疾患または損傷を診断および治療するための方法並びにキット
US11402379B2 (en) 2016-09-09 2022-08-02 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating autoimmune GFAP astrocytopathy
IT201600093825A1 (it) * 2016-09-19 2018-03-19 Fondazione St Italiano Tecnologia Composizione farmaceutica di miRNA e suoi usi terapeutici.
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
EP3545311B1 (en) * 2016-11-23 2024-03-27 Randox Laboratories Ltd Gfap derivatives for stroke diagnostics
WO2018148294A2 (en) * 2017-02-07 2018-08-16 Bioregency, Inc. S100β AND ISOFORMS FOR DETECTION OF NEUROLOGICAL CONDITIONS
MX2019009817A (es) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2018190365A1 (ja) * 2017-04-12 2018-10-18 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用
EP3610268B1 (en) 2017-04-15 2025-09-24 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
BR112019022476A2 (pt) 2017-04-28 2020-05-12 Abbott Laboratories Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
WO2018218169A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
CA3059607A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i
CN110998321A (zh) * 2017-06-02 2020-04-10 约翰霍普金斯大学 帕金森氏症患者脑脊液中par的检测方法
US20210148898A1 (en) 2017-06-02 2021-05-20 The Johns Hopkins University Detection of par in the csf of patients with parkinson's disease
US11739384B2 (en) * 2017-06-19 2023-08-29 St. John's University Circulating serum microRNA biomarkers and methods for Parkinson's disease prognosis
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
IL302108A (en) 2017-10-25 2023-06-01 Ac Immune Sa Preparations of phosphorylated tau peptides and uses thereof
JP6942036B2 (ja) * 2017-11-30 2021-09-29 藤倉化成株式会社 脳梗塞の発症リスクを高感度に検出する体液抗体バイオマーカー
CA3067055A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
BR112019028254A2 (pt) 2017-12-09 2020-07-14 Abbott Laboratories métodos para ajudar no diagnóstico e avaliação de um paciente que sofreu uma lesão ortopédica e que sofreu ou pode ter sofrido uma lesão na cabeça, tal como uma lesão cerebral traumática (lct) leve, usando a proteína ácida fibrilar glial (gfap) e/ou a hidrolase carbóxi-terminal da ubiquitina l1 (uch-l1)
EP3732489B1 (en) 2017-12-29 2025-10-22 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
KR102026675B1 (ko) * 2018-02-12 2019-09-30 강원대학교산학협력단 miR-135a-5p 및 p62에 의한 알레르기 반응 조절 메커니즘 및 이의 이용
EP4403923A3 (en) * 2018-03-08 2024-11-27 Meso Scale Technologies, LLC Genetic marker and/or biomarkers for traumatic brain injury, and ultrasensitive assays for biomarkers of traumatic brain injury
JP6499342B2 (ja) * 2018-03-19 2019-04-10 隆樹 日和佐 脳梗塞の診断マーカー
WO2019207159A1 (en) * 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
CN118460695A (zh) * 2018-07-25 2024-08-09 斯纳利蒂克斯股份有限公司 用于阿尔茨海默氏病的小rna预测因子
CN110824156B (zh) * 2018-08-14 2023-08-11 欧蒙医学诊断（中国）有限公司 神经自身免疫疾病的诊断
WO2020037311A1 (en) * 2018-08-17 2020-02-20 University Of Florida Research Foundation, Inc. Protein and peptide biomarkers for traumatic injury to the central nervous system
CN113195740A (zh) * 2018-10-17 2021-07-30 奥克斯纳健康系统公司 在脑内出血和蛛网膜下腔出血中的血浆和脑脊液miRNA生物标志物
CN109266739A (zh) * 2018-11-29 2019-01-25 成都仕康美生物科技有限公司 一种检测脑损伤的miRNA标志物、试剂盒、应用
EP3891295A4 (en) * 2018-12-04 2022-12-07 La Trobe University PROCEDURE FOR DIAGNOSIS OF A DISEASE CONDITION
CA3129252A1 (en) 2019-02-08 2020-08-13 Ac Immune S.A. Method of safe administration of phosphorylated tau peptide vaccine
CA3129034A1 (en) * 2019-02-14 2020-08-20 Marker Diagnostics Uk Limited Salivary biomarkers of brain injury
GB201909393D0 (en) * 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
CN110551809A (zh) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 miR-124在脊髓损伤修复中的用途
US11644463B2 (en) * 2019-08-30 2023-05-09 Euroimmun Medizinische Labordiagnostika Ag Detection of an autoantibody
US20230250480A1 (en) * 2020-07-09 2023-08-10 University Of Florida Research Foundation, Incorporated Biofluid-based protein and mirna biomarkers for neonatal hypoxic-ischemic encephalopathy
CN116829950A (zh) * 2020-08-24 2023-09-29 玛拉生物系统公司 用于减少母体自身抗体的方法
KR102357260B1 (ko) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트
CN113238045B (zh) * 2021-04-27 2021-12-28 南方医科大学南方医院 Crmp2及抗crmp2抗体的应用
KR102759445B1 (ko) * 2021-11-16 2025-01-24 한국한의학연구원 치료에 따른 보행 장애 개선 판별용 바이오마커 및 이의 용도
TWI853766B (zh) * 2022-12-22 2024-08-21 國立臺灣大學 用於心跳停止病患頭部電腦斷層之灰白質比率自動計算方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
ATE160821T1 (de) 1990-06-11 1997-12-15 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
WO1993003369A1 (en) * 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
US5731410A (en) 1994-11-28 1998-03-24 University Of Utah Research Foundation Peptide for blocking autoantibody-evoked activation of glutamate receptor type 3 (GLUR3)
ES2229817T3 (es) * 1998-09-08 2005-04-16 Innogenetics N.V. Uso de la tau como un marcador para la deteccion temprana del daño del sistema nervioso central (cns).
US20020002270A1 (en) 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
US6589746B1 (en) * 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20030199000A1 (en) 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20020172676A1 (en) * 2001-05-16 2002-11-21 George Jackowski Method of treatment of alzheimer's disease and device therefor
US7144708B2 (en) 2001-06-25 2006-12-05 The Cleveland Clinic Foundation Markers of blood barrier disruption and methods of using same
CA2457775A1 (en) 2001-08-20 2003-02-27 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
WO2003032894A2 (en) * 2001-10-12 2003-04-24 Pfizer Products Inc. Method of monitoring neuroprotective treatment
WO2004078204A1 (en) 2002-06-12 2004-09-16 The Cleveland Clinic Foundation Markers of blood barrier permeability and methods of using same
CA2498614C (en) 2002-09-11 2013-04-16 University Of Florida Analyzing nerve cell damage
AU2003302340B8 (en) 2002-12-24 2008-09-11 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
AU2004274710B2 (en) 2003-09-20 2011-05-19 Electrophoretics Limited Diagnostic method for brain damage-related disorders
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
EP1745149A4 (en) 2004-04-15 2008-08-06 Univ Florida NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007046811A2 (en) 2005-10-20 2007-04-26 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
JP5266459B2 (ja) 2006-02-15 2013-08-21 国立大学法人三重大学 診断用組換えプロテオリポソームの作製法
WO2007136617A2 (en) * 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
EP2024395A4 (en) 2006-05-26 2009-07-01 Biosite Inc USE OF NATRIURETIC PEPTIDES AS DIAGNOSTIC AND PROGNOSTIC INDICATORS IN VASCULAR DISEASES
JP2011511301A (ja) * 2008-02-04 2011-04-07 バンヤン・バイオマーカーズ・インコーポレイテッド 脳損傷を診断または治療するための方法
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
WO2010019553A2 (en) 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
WO2010059242A2 (en) 2008-11-21 2010-05-27 The Johns Hopkins University Neurodegenerative disease diagnostic compositions and methods of use
CA2766057A1 (en) * 2009-06-19 2010-12-23 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20120202231A1 (en) 2009-07-18 2012-08-09 Kevin Ka-Wang Wang Synergistic biomarker assay of neurological condition using s-100b
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
WO2011123844A2 (en) * 2010-04-01 2011-10-06 Banyan Biomarkers, Inc. Markers and assays for detection of neurotoxicity
WO2011160096A2 (en) 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
CN103959067B (zh) 2011-09-14 2018-04-24 促进军事医学的亨利·M·杰克逊基金会公司 用于检测和监测用于创伤后应激障碍（ptsd）的诊断生物标志物以及用于区分自杀式与非自杀式障碍的试剂盒
US20140024053A1 (en) 2012-07-20 2014-01-23 Banyan Biomarkers, Inc. Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
US20140275294A1 (en) 2013-03-15 2014-09-18 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of liver injury
WO2014194329A1 (en) 2013-05-31 2014-12-04 Banyan Biomarkers, Inc. NEURAL SPECIFIC S100β FOR BIOMARKER ASSAYS AND DEVICES FOR DETECTION OF A NEUROLOGICAL CONDITION

Also Published As

Publication number Publication date
JP2016105097A (ja) 2016-06-09
AU2016269481A1 (en) 2016-12-22
EP2478360A4 (en) 2013-04-03
ES2687469T3 (es) 2018-10-25
EP2478360B1 (en) 2018-06-27
CA2774173A1 (en) 2011-03-17
HUE040281T2 (hu) 2019-03-28
JP2017181518A (ja) 2017-10-05
AU2016269481B2 (en) 2018-08-30
AU2010291933B2 (en) 2016-09-08
JP2013504331A (ja) 2013-02-07
US20190064188A1 (en) 2019-02-28
EP2478360A2 (en) 2012-07-25
AU2010291933A1 (en) 2012-05-10
US20170242041A1 (en) 2017-08-24
WO2011032155A2 (en) 2011-03-17
WO2011032155A3 (en) 2011-10-06
US20130022982A1 (en) 2013-01-24
JP6469760B2 (ja) 2019-02-13
US10041959B2 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
JP6469760B2 (ja) ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
EP3336551B1 (en) Biomarker detection process and assay of neurological condition
AU2011235892B2 (en) Markers and assays for detection of neurotoxicity
AU2010262952B2 (en) Biomarker assay of neurological condition
US20150268252A1 (en) Biomarker assay of neurological condition
EP3115785A2 (en) Process to diagnose or treat brain injury
WO2011160096A2 (en) Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
JP6338872B2 (ja) 視神経障害発症リスクの判定方法
US7879568B2 (en) Method for the diagnosis and prognosis of demyelinating diseases
Garmy et al. Cellular isoform of the prion protein PrPc in human intestinal cell lines: genetic polymorphism at codon 129, mRNA quantification and protein detection in lipid rafts
Kovacs First Scientific Session
AU2015203660A1 (en) Process to diagnose or treat brain injury

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130619

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160229

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160328

R150 Certificate of patent or registration of utility model

Ref document number: 5909447

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250